← All trials
NCT05780307
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 23, 2023
- Primary completion
- Mar 10, 2024
- Completion date
- Oct 26, 2025
- First posted
- Mar 22, 2023
- Last posted
- Jun 7, 2023
- Enrollment
- 48
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ImmuneOnco Biopharmaceuticals (Shanghai) Co., LtdLead sponsor
- Shandong UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.